Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bladder Cancer

  Free Subscription


Articles published in BJU Int

Retrieve available abstracts of 87 articles:
HTML format



Single Articles


    June 2022
  1. JUBBER I, Mitchell S, Hussain S, Tsoi H, et al
    Social deprivation and bladder cancer: cause or affect for disparities in survival for affected women.
    BJU Int. 2022 Jun 20. doi: 10.1111/bju.15832.
    PubMed    



  2. Advances in the management of prostate and bladder cancer and recurrent urinary tract infections.
    BJU Int. 2022;129:659-660.
    PubMed    


  3. CONROY S, Hubbard R, Noon AP, Hussain SA, et al
    Case of the month from the University of Sheffield, UK: Expediting definitive treatment in patients with invasive bladder cancer: an MRI-guided pathway.
    BJU Int. 2022;129:691-694.
    PubMed    


  4. VEERATTERAPILLAY R, Geraghty R, Pandian R, Roy C, et al
    Ten-year survival outcomes after radical nephroureterectomy with a risk-stratified approach using prior diagnostic ureteroscopy: a single-institution observational retrospective cohort study.
    BJU Int. 2022;129:744-751.
    PubMed     Abstract available


  5. NURMINEN P, Ettala O, Uusitalo-Seppala R, Nummi A, et al
    Incidence of and mortality from Bacille Calmette-Guerin (BCG) infections after BCG instillation therapy.
    BJU Int. 2022;129:737-743.
    PubMed     Abstract available


    April 2022
  6. YANAGISAWA T, Sato S, Hayashida Y, Okada Y, et al
    Do we need repeat TUR after en bloc resection for pT1 bladder cancer?
    BJU Int. 2022 Apr 29. doi: 10.1111/bju.15760.
    PubMed     Abstract available


  7. ALMASSI N, Vertosick EA, Sjoberg DD, Wong NC, et al
    Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy.
    BJU Int. 2022;129:463-469.
    PubMed     Abstract available


  8. LEUNBACH TL, Stilling C, Tabor MB, Bjerggaard Jensen J, et al
    Caveats in the diagnosis of suspected non-endemic verrucous carcinoma in the urinary bladder.
    BJU Int. 2022;129:457-459.
    PubMed    


  9. SUBIELA JD, Rodriguez Faba O, Aumatell J, Calderon J, et al
    Contemporary outcomes of bladder carcinoma in situ treated with an adequate bacille Calmette-Guerin immunotherapy.
    BJU Int. 2022;129:542-550.
    PubMed     Abstract available


    March 2022
  10. MAISCH P, Koziarz A, Vajgrt J, Narayan V, et al
    Blue versus white light for transurethral resection of non-muscle invasive bladder cancer.
    BJU Int. 2022 Mar 2. doi: 10.1111/bju.15723.
    PubMed     Abstract available


  11. HASHEM A, Abdellutif MM, Laymon M, Abdullateef M, et al
    Clinical efficacy of mebeverine for persistent nocturnal enuresis after orthotopic W-neobladder.
    BJU Int. 2022;129:387-393.
    PubMed     Abstract available


  12. LEBRET T, Pignot G, Colombel M, Guy L, et al
    Artificial intelligence to improve cytology performances in bladder carcinoma detection: results of the VisioCyt test.
    BJU Int. 2022;129:356-363.
    PubMed     Abstract available


    February 2022
  13. SCHUETTFORT VM, D'Andrea D, Quhal F, Mostafaei H, et al
    A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma.
    BJU Int. 2022;129:182-193.
    PubMed     Abstract available


    January 2022
  14. VAN HOOGSTRATEN LMC, Witjes JA, Meijer RP, Ripping TM, et al
    Non-metastatic muscle-invasive bladder cancer: the role of age in receiving treatment with curative intent.
    BJU Int. 2022 Jan 22. doi: 10.1111/bju.15697.
    PubMed     Abstract available


  15. ABOZAID M, Tan WS, Khetrapal P, Baker H, et al
    Recovery of health-related quality of life in patients undergoing robot-assisted radical cystectomy with intracorporeal diversion.
    BJU Int. 2022;129:72-79.
    PubMed     Abstract available


    December 2021
  16. MEISL CJ, Karakiewicz PI, Einarsson R, Koch S, et al
    Nomograms including UBC(R) Rapid Test to detect primary bladder cancer based on a multicenter data set.
    BJU Int. 2021 Dec 20. doi: 10.1111/bju.15677.
    PubMed     Abstract available


  17. LOBO N, Hensley PJ, Bree KK, Nogueras-Gonzalez GM, et al
    Should Patients With Non-Muscle-Invasive Bladder Cancer Discontinue Fibrin Clot Inhibitors During BCG?
    BJU Int. 2021 Dec 1. doi: 10.1111/bju.15665.
    PubMed     Abstract available


    November 2021
  18. LEEMING RC, Karagas MR, Zens MS, Schned AR, et al
    Bladder Cancer Risk Variants and Overall and Disease-Specific Survival in Two Independent Cohorts.
    BJU Int. 2021 Nov 14. doi: 10.1111/bju.15640.
    PubMed     Abstract available


  19. HENSLEY PJ, Bree KK, Brooks N, Matulay J, et al
    Time interval from transurethral resection of bladder tumour to bacille Calmette-Guerin induction does not impact therapeutic response.
    BJU Int. 2021;128:634-641.
    PubMed     Abstract available


    October 2021
  20. WETTSTEIN MS, Baxter NN, Sutradhar R, Mamdani M, et al
    Oncological benefit of re-resection for T1 bladder cancer: a comparative effectiveness study.
    BJU Int. 2021 Oct 21. doi: 10.1111/bju.15622.
    PubMed     Abstract available


  21. KHADHOURI S, Gallagher KM, MacKenzie KR, Shah TT, et al
    The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer - a multicentre observational study.
    BJU Int. 2021;128:440-450.
    PubMed     Abstract available


    September 2021
  22. GORDON NS, Baxter LA, Goel A, Arnold R, et al
    Urine dna for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: A pilot study.
    BJU Int. 2021 Sep 7. doi: 10.1111/bju.15589.
    PubMed     Abstract available


  23. SARI MOTLAGH R, Mori K, Laukhtina E, Aydh A, et al
    Impact of enhanced optical techniques at time of transurethral resection of bladder tumour, with or without single immediate intravesical chemotherapy, on recurrence rate of non-muscle-invasive bladder cancer: a systematic review and network meta-anal
    BJU Int. 2021;128:280-289.
    PubMed     Abstract available


  24. GHODOUSSIPOUR S, Ladi Seyedian SS, Jiang D, Lifton J, et al
    Predictors of need for catheterisation and urinary retention after radical cystectomy and orthotopic neobladder in male patients.
    BJU Int. 2021;128:304-310.
    PubMed     Abstract available


    August 2021
  25. ELSAWY AA, Abol-Enein H, Laymon M, Ahmed AE, et al
    Predictive Value of Immunological Markers after Bacillus Calmette-Guerin Induction in Bladder Cancer.
    BJU Int. 2021 Aug 27. doi: 10.1111/bju.15582.
    PubMed     Abstract available


  26. FURRER MA, Papa N, Luetolf S, Roth B, et al
    A longitudinal study evaluating interim assessment of neoadjuvant chemotherapy for bladder cancer.
    BJU Int. 2021 Aug 21. doi: 10.1111/bju.15579.
    PubMed     Abstract available


  27. MIYATA Y, Tsurusaki T, Hayashida Y, Imasato Y, et al
    Intravesical MMC and MMC+Ara-C for non-muscle invasive bladder cancer: A randomized clinical trial.
    BJU Int. 2021 Aug 12. doi: 10.1111/bju.15571.
    PubMed     Abstract available


  28. ZHOU X, He P, Ji H, Wang C, et al
    Round ligament suspending treatment in orthotopic ileal-neobladder after radical cystectomy in women: a single-centre prospective randomised trial.
    BJU Int. 2021;128:187-195.
    PubMed     Abstract available


    July 2021
  29. LOTAN Y
    Metabolic syndrome and bladder cancer.
    BJU Int. 2021;128:1-2.
    PubMed    


    June 2021
  30. DIRIE J, Mahesan T, Hart E, Janardanan S, et al
    Delivering safe and timely cancer care during COVID-19: lessons and successes from the transition period.
    BJU Int. 2021;127:633-635.
    PubMed    


    May 2021
  31. JAHNSON S, Soderkvist P, Aljabery F, Olsson H, et al
    TERT mutation and the p53 pathway in T1 urinary bladder cancer.
    BJU Int. 2021 May 24. doi: 10.1111/bju.15490.
    PubMed     Abstract available


  32. MOE A, Liow E, Redfern A, Swarbrick N, et al
    A phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (SUBDUE-1, SUB-urothelial
    BJU Int. 2021 May 6. doi: 10.1111/bju.15365.
    PubMed     Abstract available


  33. MORTEZAVI A, Crippa A, Edeling S, Pokupic S, et al
    Morbidity and mortality after robot-assisted radical cystectomy with intracorporeal urinary diversion in octogenarians: results from the European Association of Urology Robotic Urology Section Scientific Working Group.
    BJU Int. 2021;127:585-595.
    PubMed     Abstract available


  34. D'ANDREA D, Matin S, Black PC, Petros FG, et al
    Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.
    BJU Int. 2021;127:528-537.
    PubMed     Abstract available


    April 2021
  35. RAVI P, Pond GR, Diamantopoulos LN, Su C, et al
    Optimal Pathologic Response After Neoadjuvant Chemotherapy For Muscle-Invasive Bladder Cancer: Results From A Global, Multi-Center Collaboration.
    BJU Int. 2021 Apr 28. doi: 10.1111/bju.15434.
    PubMed     Abstract available


  36. COWAN B, Klein E, Jansz K, Westenfelder K, et al
    Longitudinal Follow-up and Performance Validation of a mRNA-based Urine Test (Xpert(R) Bladder Cancer Monitor) for surveillance in Non-Muscle Invasive Bladder Cancer Patients.
    BJU Int. 2021 Apr 1. doi: 10.1111/bju.15418.
    PubMed     Abstract available


    March 2021
  37. STROTHER MC, Kutikov A, Epstein M, Bochner E, et al
    Safety of Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer and Malignant Ureteral Obstruction.
    BJU Int. 2021 Mar 29. doi: 10.1111/bju.15410.
    PubMed     Abstract available


  38. FICARRA V, Crestani A, Rossanese M, Alario G, et al
    Retrosigmoid ileal conduit without transposition of the left ureter after open radical cystectomy for bladder cancer.
    BJU Int. 2021 Mar 10. doi: 10.1111/bju.15375.
    PubMed     Abstract available


    February 2021
  39. ABRAHAMSSON J, Kollberg P, Almquist H, Blackberg M, et al
    Complete Metabolic Response with FDG-PET-CT Predicts Survival after Induction Chemotherapy in patients with Clinically Node-positive Bladder Cancer.
    BJU Int. 2021 Feb 24. doi: 10.1111/bju.15374.
    PubMed     Abstract available


  40. MIYAKE M, Nakai Y, Nishimura N, Ohnishi S, et al
    Hexylaminolevulinate-mediated fluorescent urine cytology with a novel automated detection technology for screening and surveillance of bladder cancer.
    BJU Int. 2021 Feb 12. doi: 10.1111/bju.15368.
    PubMed     Abstract available


    January 2021
  41. BREE KK, Hensley PJ, Brooks NA, Matulay J, et al
    Impact of upper tract urothelial carcinoma on response to bcg in patients with non-muscle invasive bladder cancer.
    BJU Int. 2021 Jan 22. doi: 10.1111/bju.15344.
    PubMed     Abstract available


  42. DUNSMORE J, Duncan E, Mariappan P, de Bruin M, et al
    What influences adherence to guidance for post-operative instillation of intravesical chemotherapy to bladder cancer patients?
    BJU Int. 2021 Jan 15. doi: 10.1111/bju.15336.
    PubMed     Abstract available


  43. RICHTERS A, Ripping TM, Kiemeney LA, Leliveld AM, et al
    Hospital volume is associated with postoperative mortality following radical cystectomy for treatment of bladder cancer.
    BJU Int. 2021 Jan 6. doi: 10.1111/bju.15334.
    PubMed     Abstract available


  44. FUKUOKAYA W, Kimura T, Yanagisawa T, Kimura S, et al
    Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab.
    BJU Int. 2021;127:90-95.
    PubMed     Abstract available


    December 2020
  45. STANGL FP, Thalmann GN
    Continent diversion: five decades of developments and evolution.
    BJU Int. 2020;126:653-660.
    PubMed     Abstract available


  46. MUILWIJK T, Akand M, Soria F, Giordano A, et al
    The Cancer of the Bladder Risk Assessment (COBRA) score for estimating cancer-specific survival after radical cystectomy: external validation in a large bi-institutional cohort.
    BJU Int. 2020;126:704-714.
    PubMed     Abstract available


    November 2020
  47. BROOKS NA, Kokorovic A, Xiao L, Matulay JT, et al
    The Obesity Paradox: Defining the impact of Body Mass Index and Diabetes Mellitus for patients with Non-Muscle Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin.
    BJU Int. 2020 Nov 14. doi: 10.1111/bju.15296.
    PubMed     Abstract available


  48. SORIA F, Black PC, Fairey AS, Cookson MS, et al
    Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis.
    BJU Int. 2020 Nov 5. doi: 10.1111/bju.15289.
    PubMed     Abstract available


  49. DEL GIUDICE F, Leonardo C, Simone G, Pecoraro M, et al
    Preoperative detection of Vesical Imaging-Reporting and Data System (VI-RADS) score 5 reliably identifies extravesical extension of urothelial carcinoma of the urinary bladder and predicts significant delayed time to cystectomy: time to reconsider the
    BJU Int. 2020;126:610-619.
    PubMed     Abstract available


    October 2020
  50. SPENCER-BOWDAGE S, Russell B, Rigby J, O'Kelly J, et al
    The experience of UK bladder cancer patients during the COVID-19 pandemic: A survey-based snapshot.
    BJU Int. 2020 Oct 30. doi: 10.1111/bju.15287.
    PubMed     Abstract available


  51. KARDOUST PARIZI M, Shariat SF, Margulis V, Mori K, et al
    Tumor infiltrating immune cells to predict response to intravesical BCG in Patients with Non-muscle invasive Bladder Cancer: A Systematic Review and meta-analysis.
    BJU Int. 2020 Oct 18. doi: 10.1111/bju.15276.
    PubMed     Abstract available


  52. HOSSEINI A, Mortezavi A, Sjoberg S, Laurin O, et al
    Robot-assisted intracorporeal orthotopic bladder substitution after radical cystectomy: perioperative morbidity and oncological outcomes - a single-institution experience.
    BJU Int. 2020;126:464-471.
    PubMed     Abstract available


    September 2020
  53. LENFANT L, Cancel-Tassin G, Gazut S, Comperat E, et al
    Genetic variability in 13q33 and 9q34 is linked to Aggressiveness Patterns and a Higher risk of progression of Non-Muscle-Invasive Bladder Cancer at the time of Diagnosis.
    BJU Int. 2020 Sep 25. doi: 10.1111/bju.15254.
    PubMed     Abstract available


  54. CACCIAMANI G, Aron M, Gill I, Desai M, et al
    Oncological outcome according to attainment of pentafecta after robot assisted radical cystectomy among bladder cancer patients using KORARC database (730 multicenter robot radical cystectomy database) BJU Int 2020 Jul 8. doi: 10.1111/ bju.15178.
    BJU Int. 2020 Sep 1. doi: 10.1111/bju.15222.
    PubMed     Abstract available


  55. VAN DER VLIES E, Los M, Stijns PEF, van Hengel M, et al
    Preoperative frailty and outcome in patients undergoing radical cystectomy.
    BJU Int. 2020;126:388-395.
    PubMed     Abstract available


    August 2020
  56. KOHADA Y, Hayashi T, Hsi RS, Yukihiro K, et al
    Recurrence and Progression Free Survival of Intermediate Risk Non-Muscle Invasive Bladder Cancer: The impact of Conditional Evaluation and Sub-Classification.
    BJU Int. 2020 Aug 17. doi: 10.1111/bju.15209.
    PubMed     Abstract available


  57. MONTORSI F, Moschini M, Necchi A
    CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer.
    BJU Int. 2020 Aug 17. doi: 10.1111/bju.15214.
    PubMed     Abstract available


  58. LEE SH, Mahendran R, Tham SM, Thamboo TP, et al
    Tryptophan/kynurenine ratio as biomarker of bladder cancer.
    BJU Int. 2020 Aug 13. doi: 10.1111/bju.15205.
    PubMed     Abstract available


  59. LEE SH, Mahendran R, Tham SM, Thamboo TP, et al
    Combination Bacillus Calmette-Guerin and indoleamine 2,3-dioxygenase 1 inhibitor therapy of murine orthotopic bladder cancer.
    BJU Int. 2020 Aug 8. doi: 10.1111/bju.15201.
    PubMed     Abstract available


  60. ALJABERY F, Liedberg F, Haggstrom C, Strock V, et al
    Treatment and prognosis of bladder cancer patients with other primary cancers. A nationwide population-based study in the Bladder Cancer Data Base Sweden (BladderBaSe).
    BJU Int. 2020 Aug 6. doi: 10.1111/bju.15198.
    PubMed     Abstract available


  61. GONTERO P, Montanari E, Roupret M, Longo F, et al
    Comparison of the performance of ADXBLADDER test and urinary Cytology in the follow up of Non-Muscle Invasive Bladder Cancer: a blinded prospective multicentric study.
    BJU Int. 2020 Aug 3. doi: 10.1111/bju.15194.
    PubMed     Abstract available


  62. GALLAGHER KM, Bhatt NR, Clement K, Kulkarni M, et al
    Study launch: transurethral REsection and Single instillation intra-vesical chemotherapy Evaluation in bladder Cancer Treatment (RESECT).
    BJU Int. 2020;126:310-311.
    PubMed    


  63. HUSSEIN AA, Elsayed AS, Aldhaam NA, Jing Z, et al
    A comparative propensity score-matched analysis of perioperative outcomes of intracorporeal vs extracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium.
    BJU Int. 2020;126:265-272.
    PubMed     Abstract available


    July 2020
  64. OH JJ, Lee S, Ku JH, Kwon TG, et al
    Oncological outcome according to attainment of pentafecta after robot assisted radical cystectomy among bladder cancer patients using KORARC database (730 multicenter robot radical cystectomy database).
    BJU Int. 2020 Jul 18. doi: 10.1111/bju.15178.
    PubMed     Abstract available


  65. ELKASHEF A, Barakat N, Khater SM, Awadalla A, et al
    Effect of Low Energy Shock Wave Therapy on Intravesical Epirubicin Delivery in a Rat Model of Bladder Cancer.
    BJU Int. 2020 Jul 12. doi: 10.1111/bju.15173.
    PubMed     Abstract available


  66. LOTAN Y, Chaplin I, Ahmadi H, Meng X, et al
    Prospective evaluation of blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer.
    BJU Int. 2020 Jul 10. doi: 10.1111/bju.15166.
    PubMed     Abstract available


    June 2020
  67. GAKIS G, Karl A, Bertz S, Burger M, et al
    Transurethral en bloc submucosal hydrodissection versus conventional resection for resection of non-muscle invasive bladder cancer (HYBRIDBLUE): a randomized, multicentre trial.
    BJU Int. 2020 Jun 23. doi: 10.1111/bju.15150.
    PubMed     Abstract available


  68. SARI MOTLAGH R, Mori K, Miura N, Quhal F, et al
    The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumor and benign prostatic hyperplasia; a systematic review and meta-analysis.
    BJU Int. 2020 Jun 21. doi: 10.1111/bju.15146.
    PubMed     Abstract available


  69. HENTSCHEL AE, van EE, der Toom, Vis AN, et al
    A Systematic Review on Mutation Markers for Bladder Cancer Diagnosis in Urine.
    BJU Int. 2020 Jun 15. doi: 10.1111/bju.15137.
    PubMed     Abstract available


  70. MCCLOSKEY H, Hamad J, Smith AB
    How can we motivate patients with bladder cancer to help themselves?
    BJU Int. 2020;125:751-752.
    PubMed    


    March 2020
  71. MANNION L, Bosco C, Nair R, Mullassery V, et al
    Overall survival, disease specific survival and local recurrence outcomes in patients with muscle invasive bladder cancer treated with external beam radiotherapy and brachytherapy: A systematic review.
    BJU Int. 2020 Mar 7. doi: 10.1111/bju.15047.
    PubMed     Abstract available


  72. MOSTAFID AH, Porta N, Cresswell J, Griffiths T, et al
    CALIBER - A phase II randomised feasibility trial of chemoablation with mitomycin versus surgical management in low risk non-muscle invasive bladder cancer.
    BJU Int. 2020 Mar 3. doi: 10.1111/bju.15038.
    PubMed     Abstract available


    February 2020
  73. JANISCH F, Rink M, Shariat SF
    The promise and challenges of neoadjuvant immunotherapy in the management of non-metastatic muscle-invasive bladder cancer.
    BJU Int. 2020 Feb 3. doi: 10.1111/bju.15025.
    PubMed     Abstract available


  74. SAAD M, Moschini M, Stabile A, Macek P, et al
    Long-term functional and oncological outcomes of nerve-sparing and prostate capsule-sparing cystectomy: a single-centre experience.
    BJU Int. 2020;125:253-259.
    PubMed     Abstract available


    January 2020
  75. CHUNG J, Maganti M, Kulkarni GS, Morash R, et al
    Modifiable Lifestyle Behaviours Impact the Health-Related Quality of Life of Bladder Cancer Survivors.
    BJU Int. 2020 Jan 24. doi: 10.1111/bju.15007.
    PubMed     Abstract available


  76. TAN WS, Teo CH, Chan D, Ang KM, et al
    Exploring patients' experience and perception of being diagnosed with bladder cancer: A mixed methods approach.
    BJU Int. 2020 Jan 23. doi: 10.1111/bju.15008.
    PubMed     Abstract available


  77. MATULAY JT, Soloway M, Witjes JA, Buckley R, et al
    Risk Adapted Management of Low-Grade Bladder Tumors: Recommendations from the International Bladder Cancer Group.
    BJU Int. 2020 Jan 16. doi: 10.1111/bju.14995.
    PubMed     Abstract available


  78. MOSSANEN M, Chang SL
    Beyond bladder cancer surveillance: building a survivorship clinic.
    BJU Int. 2020;125:2-3.
    PubMed    


  79. CACCIAMANI GE, Winter M, Medina LG, Ashrafi AN, et al
    Radical cystectomy pentafecta: a proposal for standardisation of outcomes reporting following robot-assisted radical cystectomy.
    BJU Int. 2020;125:64-72.
    PubMed     Abstract available


    October 2019
  80. TAYLOR J, Becher E, Steinberg GD
    Update on the Guideline of Guidelines: Non-Muscle Invasive Bladder Cancer.
    BJU Int. 2019 Oct 9. doi: 10.1111/bju.14915.
    PubMed     Abstract available


    July 2019
  81. HAMPSON A, Vincent A, Dasgupta P, Vasdev N, et al
    Radical cystectomy complications and perioperative mortality.
    BJU Int. 2019;124:3-4.
    PubMed    


    June 2019
  82. DOYLE E, Crew J, Mostafid H, Tuthill M, et al
    Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of non-muscle-invasive disease.
    BJU Int. 2019;123:947-958.
    PubMed     Abstract available


    May 2019
  83. MAZZONE E, Mistretta FA, Knipper S, Palumbo C, et al
    Long-Term Incidence of Secondary Bladder, Rectal Cancer in Patients Treated with Brachytherapy for Localized Prostate Cancer: A Large-Scale Population-Based Analysis.
    BJU Int. 2019 May 30. doi: 10.1111/bju.14841.
    PubMed     Abstract available


    March 2019
  84. KHETRAPAL P, Kelly JD, Catto JWF, Vasdev N, et al
    Does the robot have a role in radical cystectomy?
    BJU Int. 2019;123:380-382.
    PubMed    


    February 2019
  85. DHARIWAL R, Pindoria N, Dasgupta P, Khan MS, et al
    #Checkmate: could checkpoint inhibitors be the game changer in the fight against metastatic urothelial carcinoma?
    BJU Int. 2019;123:203-207.
    PubMed    


  86. NURMINEN P, Ettala O, Seppanen M, Taimen P, et al
    Urine cytology is a feasible tool for assessing erythematous bladder lesions after bacille Calmette-Guerin (BCG) treatment.
    BJU Int. 2019;123:246-251.
    PubMed     Abstract available


  87. KINNEAR N, O'Callaghan M, Hennessey D, Liddell H, et al
    Intra-operative cell salvage in urological surgery: a systematic review and meta-analysis of comparative studies.
    BJU Int. 2019;123:210-219.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: